Skip to content
PeptideFactSheets
Plain-English comparison

Next-generation metabolic peptides: beyond GLP-1 alone

How amylin analogs and glucagon-containing co-agonists differ in targets, trial maturity, liver research, weight evidence, and FDA status.

By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.

The quick overview

The next metabolic wave is not one drug class. Pramlintide and cagrilintide target amylin biology; retatrutide combines GLP-1, GIP, and glucagon activity; survodutide and pemvidutide combine GLP-1 and glucagon signaling.

Pramlintide has a narrow diabetes approval. The other candidates remain investigational even when large or positive trials exist. Combination results, especially CagriSema, cannot be assigned entirely to one component.

Side-by-side comparison

Pramlintide
FDA approved for specific usesStrong human evidence for approved uses

Studied for

Glucose control with mealtime insulin · Satiety and food intake · Obesity and weight outcomes

Cagrilintide
In clinical trialsModerate human evidence

Studied for

Obesity and overweight · Type 2 diabetes · Blood pressure and cardiometabolic markers

Retatrutide
In clinical trialsEarly human evidence

Studied for

Obesity and overweight · Type 2 diabetes · Cardiovascular and kidney outcomes

Survodutide
In clinical trialsModerate human evidence

Studied for

Obesity · Metabolic dysfunction-associated steatohepatitis · Liver fat and fibrosis

Pemvidutide
In clinical trialsEarly human evidence

Studied for

MASH and MASLD · Liver fat · Obesity

Approved versus investigational

An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.

What researchers are studying

  • Obesity and chronic weight management
  • Type 2 diabetes and glucose control
  • MASH, liver fat, and fibrosis
  • Amylin, glucagon, GLP-1, and GIP pathway combinations

Risks and reasons for caution

  • A Phase 3 result or accepted trial endpoint is not an FDA approval.
  • Weight, liver-fat imaging, MASH resolution, and fibrosis are different outcomes.
  • Gastrointestinal tolerability, discontinuation, and long-term clinical outcomes can materially change the benefit-risk picture.

What remains uncertain

  • Which investigational products will receive approval and for which exact populations
  • Long-term cardiovascular, liver, gallbladder, pancreatic, and metabolic outcomes
  • How much benefit and harm each receptor target contributes

Questions to ask a healthcare professional

1. Is the evidence for the peptide alone or a fixed combination?

2. Was the primary endpoint weight, liver fat, biopsy, fibrosis, or a clinical event?

3. Is the product approved for this exact use?

4. How did discontinuation and incomplete treatment affect the result?

Plain-English takeaway

Next-generation metabolic peptides are diversifying beyond GLP-1, but receptor count is not a ranking system. Approval, endpoint, population, tolerability, and long-term outcomes matter more than mechanistic novelty.

References

  1. 1
    FDA prescribing information: Symlin

    The narrow approved amylin-analog benchmark and its boxed warning.

  2. 2
    REDEFINE 1 cagrilintide-semaglutide trial

    Phase 3 evidence including combination and individual-component groups.

  3. 3
    Survodutide Phase 2 obesity trial

    Controlled dual glucagon/GLP-1 obesity evidence.

  4. 4
    Pemvidutide IMPACT MASH trial

    Mid-stage biopsy evidence and remaining fibrosis uncertainty.